Report Detail
Global Biosimilars Insulin Market Research Report 2019
- RnM3122523 |
- 14 March, 2019 |
- Global |
- 93 Pages |
- QYResearch |
- Pharma & Healthcare
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
The global Biosimilars Insulin market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Biosimilars Insulin volume and value at global level, regional level and company level. From a global perspective, this report represents overall Biosimilars Insulin market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Eli Lilly
Boehringer Ingelheim
Merck
Pfizer
Biocon
Mylan
...
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Insulin Glargine Basaglar
Insulin Lantus
Segment by Application
Type I Diabetes
Type II Diabetes
Table of Contents
Executive Summary
1 Biosimilars Insulin Market Overview
- 1.1 Product Overview and Scope of Biosimilars Insulin
- 1.2 Biosimilars Insulin Segment by Type
- 1.2.1 Global Biosimilars Insulin Production Growth Rate Comparison by Type (2014-2025)
- 1.2.2 Insulin Glargine Basaglar
- 1.2.3 Insulin Lantus
- 1.3 Biosimilars Insulin Segment by Application
- 1.3.1 Biosimilars Insulin Consumption Comparison by Application (2014-2025)
- 1.3.2 Type I Diabetes
- 1.3.3 Type II Diabetes
- 1.4 Global Biosimilars Insulin Market by Region
- 1.4.1 Global Biosimilars Insulin Market Size Region
- 1.4.2 North America Status and Prospect (2014-2025)
- 1.4.3 Europe Status and Prospect (2014-2025)
- 1.4.4 China Status and Prospect (2014-2025)
- 1.4.5 Japan Status and Prospect (2014-2025)
- 1.5 Global Biosimilars Insulin Market Size
- 1.5.1 Global Biosimilars Insulin Revenue (2014-2025)
- 1.5.2 Global Biosimilars Insulin Production (2014-2025)
2 Global Biosimilars Insulin Market Competition by Manufacturers
- 2.1 Global Biosimilars Insulin Production Market Share by Manufacturers (2014-2019)
- 2.2 Global Biosimilars Insulin Revenue Share by Manufacturers (2014-2019)
- 2.3 Global Biosimilars Insulin Average Price by Manufacturers (2014-2019)
- 2.4 Manufacturers Biosimilars Insulin Production Sites, Area Served, Product Types
- 2.5 Biosimilars Insulin Market Competitive Situation and Trends
- 2.5.1 Biosimilars Insulin Market Concentration Rate
- 2.5.2 Biosimilars Insulin Market Share of Top 3 and Top 5 Manufacturers
- 2.5.3 Mergers & Acquisitions, Expansion
3 Global Biosimilars Insulin Production Market Share by Regions
- 3.1 Global Biosimilars Insulin Production Market Share by Regions
- 3.2 Global Biosimilars Insulin Revenue Market Share by Regions (2014-2019)
- 3.3 Global Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 3.4 North America Biosimilars Insulin Production
- 3.4.1 North America Biosimilars Insulin Production Growth Rate (2014-2019)
- 3.4.2 North America Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 3.5 Europe Biosimilars Insulin Production
- 3.5.1 Europe Biosimilars Insulin Production Growth Rate (2014-2019)
- 3.5.2 Europe Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 3.6 China Biosimilars Insulin Production (2014-2019)
- 3.6.1 China Biosimilars Insulin Production Growth Rate (2014-2019)
- 3.6.2 China Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 3.7 Japan Biosimilars Insulin Production (2014-2019)
- 3.7.1 Japan Biosimilars Insulin Production Growth Rate (2014-2019)
- 3.7.2 Japan Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
4 Global Biosimilars Insulin Consumption by Regions
- 4.1 Global Biosimilars Insulin Consumption by Regions
- 4.2 North America Biosimilars Insulin Consumption (2014-2019)
- 4.3 Europe Biosimilars Insulin Consumption (2014-2019)
- 4.4 China Biosimilars Insulin Consumption (2014-2019)
- 4.5 Japan Biosimilars Insulin Consumption (2014-2019)
5 Global Biosimilars Insulin Production, Revenue, Price Trend by Type
- 5.1 Global Biosimilars Insulin Production Market Share by Type (2014-2019)
- 5.2 Global Biosimilars Insulin Revenue Market Share by Type (2014-2019)
- 5.3 Global Biosimilars Insulin Price by Type (2014-2019)
- 5.4 Global Biosimilars Insulin Production Growth by Type (2014-2019)
6 Global Biosimilars Insulin Market Analysis by Applications
- 6.1 Global Biosimilars Insulin Consumption Market Share by Application (2014-2019)
- 6.2 Global Biosimilars Insulin Consumption Growth Rate by Application (2014-2019)
7 Company Profiles and Key Figures in Biosimilars Insulin Business
- 7.1 Eli Lilly
- 7.1.1 Eli Lilly Biosimilars Insulin Production Sites and Area Served
- 7.1.2 Biosimilars Insulin Product Introduction, Application and Specification
- 7.1.3 Eli Lilly Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 7.1.4 Main Business and Markets Served
- 7.2 Boehringer Ingelheim
- 7.2.1 Boehringer Ingelheim Biosimilars Insulin Production Sites and Area Served
- 7.2.2 Biosimilars Insulin Product Introduction, Application and Specification
- 7.2.3 Boehringer Ingelheim Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 7.2.4 Main Business and Markets Served
- 7.3 Merck
- 7.3.1 Merck Biosimilars Insulin Production Sites and Area Served
- 7.3.2 Biosimilars Insulin Product Introduction, Application and Specification
- 7.3.3 Merck Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 7.3.4 Main Business and Markets Served
- 7.4 Pfizer
- 7.4.1 Pfizer Biosimilars Insulin Production Sites and Area Served
- 7.4.2 Biosimilars Insulin Product Introduction, Application and Specification
- 7.4.3 Pfizer Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 7.4.4 Main Business and Markets Served
- 7.5 Biocon
- 7.5.1 Biocon Biosimilars Insulin Production Sites and Area Served
- 7.5.2 Biosimilars Insulin Product Introduction, Application and Specification
- 7.5.3 Biocon Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 7.5.4 Main Business and Markets Served
- 7.6 Mylan
- 7.6.1 Mylan Biosimilars Insulin Production Sites and Area Served
- 7.6.2 Biosimilars Insulin Product Introduction, Application and Specification
- 7.6.3 Mylan Biosimilars Insulin Production, Revenue, Price and Gross Margin (2014-2019)
- 7.6.4 Main Business and Markets Served
8 Biosimilars Insulin Manufacturing Cost Analysis
- 8.1 Biosimilars Insulin Key Raw Materials Analysis
- 8.1.1 Key Raw Materials
- 8.1.2 Price Trend of Key Raw Materials
- 8.1.3 Key Suppliers of Raw Materials
- 8.2 Proportion of Manufacturing Cost Structure
- 8.3 Manufacturing Process Analysis of Biosimilars Insulin
- 8.4 Biosimilars Insulin Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.2 Biosimilars Insulin Distributors List
- 9.3 Biosimilars Insulin Customers
10 Market Dynamics
- 10.1 Market Trends
- 10.2 Opportunities
- 10.3 Market Drivers
- 10.4 Challenges
- 10.5 Influence Factors
11 Global Biosimilars Insulin Market Forecast
- 11.1 Global Biosimilars Insulin Production, Revenue Forecast
- 11.1.1 Global Biosimilars Insulin Production Growth Rate Forecast (2019-2025)
- 11.1.2 Global Biosimilars Insulin Revenue and Growth Rate Forecast (2019-2025)
- 11.1.3 Global Biosimilars Insulin Price and Trend Forecast (2019-2025)
- 11.2 Global Biosimilars Insulin Production Forecast by Regions (2019-2025)
- 11.2.1 North America Biosimilars Insulin Production, Revenue Forecast (2019-2025)
- 11.2.2 Europe Biosimilars Insulin Production, Revenue Forecast (2019-2025)
- 11.2.3 China Biosimilars Insulin Production, Revenue Forecast (2019-2025)
- 11.2.4 Japan Biosimilars Insulin Production, Revenue Forecast (2019-2025)
- 11.3 Global Biosimilars Insulin Consumption Forecast by Regions (2019-2025)
- 11.3.1 North America Biosimilars Insulin Consumption Forecast (2019-2025)
- 11.3.2 Europe Biosimilars Insulin Consumption Forecast (2019-2025)
- 11.3.3 China Biosimilars Insulin Consumption Forecast (2019-2025)
- 11.3.4 Japan Biosimilars Insulin Consumption Forecast (2019-2025)
- 11.4 Global Biosimilars Insulin Production, Revenue and Price Forecast by Type (2019-2025)
- 11.5 Global Biosimilars Insulin Consumption Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Biosimilars Insulin . Industry analysis & Market Report on Biosimilars Insulin is a syndicated market report, published as Global Biosimilars Insulin Market Research Report 2019. It is complete Research Study and Industry Analysis of Biosimilars Insulin market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
